Last reviewed · How we verify

NCT04327804

A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research

Completed Last updated 11 April 2022
What this trial tests

trial testing Odd/Even birth year intervention groups in SARS-CoV Infection in 139 participants. Completed in 10 October 2020.

Timeline
25 March 2020
Primary endpoint
18 August 2020
10 October 2020

Quick facts

Lead sponsorUnitedHealth Group
StatusCompleted
Study typeOBSERVATIONAL
Enrollment139
Start date25 March 2020
Primary completion18 August 2020
Estimated completion10 October 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

UnitedHealth Group — full company profile →

Who can join

Eligibility, any sex, with SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Minimal risk research study: 1. Comparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus; 2. Quantifying the development and trajectory of the disease through clinic visits and blood values.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19).
    Verma HK, Merchant N, Verma MK, Kuru Cİ, et al · · 2020 · cited 21× · PMID 32792167 · DOI 10.1016/j.bj.2020.07.008

Verify or expand the search:

Other recruiting trials for SARS-CoV Infection

Currently open trials in the same condition.

Other UnitedHealth Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04327804.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing